New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 28, 2014
08:58 EDTBTXBioTime receives ISO 13485 certification for medical devices
BioTime announced that it has received ISO 13485:2003 certification from British Standards Institution for design, development, manufacture, and distribution of BioTime HyStem hydrogels for cell delivery applications. If Renevia is approved for the treatment of HIV-related facial lipoatrophy, BioTime plans to seek to expand its uses into other cell-based applications in reconstructive surgeries, traumatic injuries, and age-related lipoatrophy. BioTime’s plan is to bring Renevia to the medical market first in the E.U., where the regulatory pathway will allow for faster approval than in the U.S. Once the use of Renevia is established in Europe, BioTime will address an even larger potential market in Asia and the U.S.
News For BTX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 2, 2015
09:03 EDTBTXBioTime agrees to sell $5.1M of equity
Subscribe for More Information
September 30, 2015
05:33 EDTBTXHeraeus Medical and BioTime subsidiary enter into exclusive worldwide agreement
Heraeus Medical GmbH and BioTime announced that BioTime's subsidiary OrthoCyte Corporation and Heraeus Medical have entered into exclusive development and worldwide licensing agreements for the development of innovative bone grafting therapies based on the use of BioTime's proprietary PureStem human embryonic progenitor cell technology. Under the terms of the development agreement, Heraeus Medical would make an initial $1M upfront payment to OrthoCyte, and additional payments upon OrthoCyte's attainment of certain product development milestones, and Heraeus will fund all ongoing product development activities through IND submission. Heraeus Medical will be responsible for worldwide sales if a product is successfully developed, can be demonstrated through clinical trials to be safe and effective, and receives regulatory approval for marketing. OrthoCyte will be responsible for product development and initially for manufacturing. Pursuant to the terms of the license agreement, OrthoCyte has licensed certain technology to Heraeus, and Heraeus has licensed certain technology to OrthoCyte. The license grant by OrthoCyte to Heraeus is exclusive and worldwide in the field of bone grafting for all osteoskeleton diseases and injuries, except oral maxillofacial. The license grant by Heraeus to OrthoCyte is exclusive and worldwide in all other fields. Pursuant to the license agreement, each of Heraeus and OrthoCyte will pay certain specified royalties to each other based on their respective net sales of the product developed under the development agreement.
September 28, 2015
08:04 EDTBTXBioTime, Cell Cure Neurosciences receive FDA fast track designation for OpRegen
Subscribe for More Information
September 25, 2015
17:10 EDTBTXBioTime to sell $20.7M of common stock in registered direct offering
BioTime announced that it has agreed to sell up to $20.7M of its common shares in a registered direct offering to select investment funds in Israel that hold shares of companies that are included within certain stock indexes of the Tel Aviv Stock Exchange. The price per share will be determined with reference to the closing price of BioTime common shares on the TASE on the trading day immediately preceding the first day on which BioTime common shares enter the TASE stock indexes. The sale of the common shares is expected to close on or about October 1, 2015, subject to the satisfaction of customary closing conditions. The amount of aggregate proceeds from the sale and the total number of shares sold will depend upon the market price of BioTime common shares and the number of BioTime common shares the investment funds need to purchase from BioTime to put their portfolios in balance with the TASE stock indexes that they track. BioTime will pay Union Underwriting & Finances Ltd an investment banking fee in the amount of 1% of the aggregate purchase price of the common shares sold.

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use